<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
VERU
Veru
$
()


  • Veru initiated with bullish view at Raymond James, here's why

    3/27/2024 - 16:19pm
  • Veru appoints Louis Arrone as chief medical advisor for Enobosarm program

    3/12/2024 - 08:17am
  • Veru receives Nasdaq notification on delayed quarterly report

    2/27/2024 - 19:16pm
  • Veru announces new scientific advisory board for enobosarm program

    2/20/2024 - 08:45am
  • Veru reports Q1 revenue $2.1M vs. $2.5M last year

    2/8/2024 - 07:21am
  • Veru announces FDA clearance of IND application for Phase 2b with enobosarm

    2/6/2024 - 08:34am
  • Veru submits IND application to FDA for development of enobosarm

    1/8/2024 - 08:43am
  • Veru to host investor call to discuss financing, enobosarm strategy

    12/19/2023 - 08:34am
  • Veru prices 45.8M shares at 72c in underwritten public offering

    12/14/2023 - 09:09am
  • Veru $25M Spot Secondary re-offered at 72c

    12/13/2023 - 16:22pm
  • Veru files to sell common stock, no amount given

    12/13/2023 - 16:02pm
  • Veru management to meet virtually with Jefferies

    10/26/2023 - 13:26pm
  • Veru reports muscle data from five studies of enobosarm

    10/4/2023 - 08:38am
  • Veru reaches agreement with FDA on Phase 3 trial for sabizabulin

    9/26/2023 - 08:41am
  • Veru reports clinical data from discontinued ARTEST study

    9/11/2023 - 07:06am
dynamic_feed Breaking News